Decentralized Clinical Trials: From Technology Adoption to Patient-Centric Design

The COVID-19 pandemic provided an important backdrop for the accelerated adoption of decentralized clinical trials (DCTs). In recent years, as digital health technologies (DHTs), telemedicine, wearable devices, and artificial intelligence (AI) continue to evolve, the use of DCTs in global clinical research has continued to expand and is gradually moving toward scale and integration.

Although digital tools were initially designed to address operational bottlenecks in traditional trials, early implementation often created fragmented workflows. Today, clinical research is shifting from simply adopting technology to building a coordinated, patient-centric integrated model.

What Are Decentralized Clinical Trials (DCTs)?

In standard research practice, decentralized clinical trials refer to studies where some or all trial-related activities occur outside traditional physical trial sites. By using connected health devices, home healthcare visits, telemedicine, and direct-to-patient logistics, DCTs bring research procedures directly to participants in their local communities or homes.

Background: The Emergence of DCTs

Traditional clinical trials depend almost entirely on physical, brick-and-mortar research sites. Under this conventional setup, participants frequently encounter geographic barriers, travel expenses, and scheduling conflicts that impede enrollment and protocol adherence.

During the COVID-19 pandemic, these mobility constraints prompted the rapid implementation of remote trial solutions as an emergency response. As the operating landscape stabilized, sponsors recognized that remote methodologies could serve as strategic models to support trial resilience and participant engagement.

DCTs vs. Traditional Clinical Trials

Similarities

Traditional clinical trials and DCTs are built on the same ethical, regulatory, and scientific foundations. Both models are required to comply with Good Clinical Practice (GCP) and applicable international guidelines, including ICH E6 (GCP) and its latest revisions.

Under both frameworks, investigational medical products must be systematically tracked, participants must provide comprehensive informed consent, and principal investigators retain ultimate medical oversight and legal responsibility for trial conduct.

Differences

The primary differences between the two models center on visit location, data acquisition frequency, and logistics:

Types of DCTs

Decentralized research does not follow an all-or-nothing approach. In industry practice, virtual clinical trials are classified into three operational models:

· Fully Decentralized Trials: All screening, informed consent, product administration, and safety follow-ups occur remotely without physical clinic visits. In our three-year survey tracking (n=2,776), fully remote clinical trials declined from 19.9% in 2023 to 9.1% in 2024, before stabilizing at 13.6% in 2025.

· Hybrid Clinical Trials: These protocols selectively combine traditional on-site visits with remote operational components. Hybrid clinical trials represent the primary operational model across the industry, demonstrating consistent adoption rates of 32.4% in 2023, 29.4% in 2024, and 31.1% in 2025.

· Traditional Site-Based Trials with Digital Support: Conventional site execution supported by isolated point solutions, such as electronic data capture.

Sources

All data in this article are based on Tigermed’s white paper: From Adoption to Integration: A Three-Year Evolution of Decentralized Clinical Trials in the Era of AI and Digital Health Technologies (June 2026). In the event of any updates, the latest version of the white paper shall prevail.

Three Key Advantages of DCTs

1. Improving Participant Accessibility and Recruitment Efficiency

Geographic distance often limits patient accrual in conventional site-based studies. By enabling remote pre-screening and home-based procedures, decentralized trials expand recruitment reach into regional and underserved populations. This decentralization helps compress recruitment timelines and broadens demographic diversity.

2. Enhancing the Participant Experience and Retention Rates

Frequent travel to investigative centers can cause substantial participant fatigue, leading to protocol dropouts. Incorporating home nursing visits, direct drug delivery, and virtual consultations allows patients to participate within their everyday routines, supporting treatment compliance and long-term retention.

3. Enabling More Continuous Data Collection and Improving Real-World Relevance

Standard clinical evaluations provide periodic snapshots that are vulnerable to patient recall bias. By deploying medical-grade digital health technologies, studies can capture continuous, objective physiological measurements in real-world settings.

In our survey, 32.5% of stakeholders cited enhancing data objectivity and continuity as their primary rationale for adopting digital tools, while 23.1% used them to support novel digital endpoint development.

Key Technologies and Service Modules of DCT

DCT implementation relies on integrated technical and operational capabilities across two levels:

For Investigational Sites and Clinical Operations

· E2E: Utilizes large language models to extract protocol variables from electronic source data directly into EDC, improving data timeliness and quality while reducing overall costs.

· eConsent: Delivers remote visual informed consent, ensuring trial participants receive study information thoroughly and promptly.

· eCOA: Standardizes electronic clinical data evaluations to elevate data reliability and workflow efficiency across clinical sites.

· TeleVisit: Facilitates secure remote study visits, enabling direct and convenient communication between investigators and participants.

· Remote Recruitment: Digital screening tools that evaluate candidate eligibility using structured digital pathways.

· Remote Monitoring: Enables clinical monitors to review electronic source records and track safety signals off-site via secure platforms, ensuring real-time data integrity while reducing on-site monitoring expenditures.

For Participants and Decentralized Operations

· IRT/DTP: Combines direct-to-patient distribution with medication traceability coding, enhancing dosing convenience while safeguarding protocol blinding integrity.

· ePRO/eDiary: Captures patient-reported outcomes directly, supporting participant compliance while enhancing data quality and collection efficiency.

· ePAY: Provides automated third-party stipend payments, reducing participant financial burdens and safeguarding participant rights.

· DHT/Digital Medicine: Deploys a comprehensive digital healthcare framework to empower continuous, objective clinical data collection.

· CTRM & RBQM: Integrates remote monitoring with risk-based centralized monitoring, enhancing study quality while controlling clinical trial expenditures.

Deploying these DCT technology components and DCT elements within a cohesive ecosystem helps reduce operational fragmentation across study teams.

Which Clinical Studies Are Suited for DCTs?

Suitability depends on trial phase, protocol complexity, and drug safety profiles. Survey data show a distinct transition away from exploratory and post-marketing settings toward critical commercial phases:

— In 2023, decentralized methods were concentrated in Phase IV surveillance (54.8%), real-world studies (32.3%), and investigator-initiated trials (IITs; 29.6%).

— By 2025, Phase IV application decreased to 11.8%, and investigator-initiated trials declined to 8.8%. Conversely, DCT utilization in pivotal commercial trials remained strong in 2025, accounting for 19.7% in Phase II and 25.2% in Phase III studies.

Common Global Applications of DCTs

Globally, decentralized clinical trial elements are widely applied across key therapeutic areas, including:

· Rare Diseases

· Oncology

· Central Nervous System (CNS) Disorders

· Cardiovascular and Metabolic Conditions

In China, research findings indicate that decentralized trial adoption is mainly concentrated in therapeutic areas with large patient populations and high clinical demand.

l Oncology maintained the highest DCT adoption rate, stabilizing at 12.2% in 2025, followed by cardiovascular and metabolic diseases at 10.8%, dermatology at 7.8%, CNS disorders at 7.2%, and hematology at 5.2%.

Key Implementation and Operational Challenges in DCTs

As DCTs advance toward scale and integration, early deployments designed to solve traditional trial bottlenecks have exposed new layers of operational friction. In evaluating this transition, research findings identify several key structural, operational, and regulatory challenges:

· Platform Fragmentation and Digital Overload: Deploying multiple disconnected digital tools creates workflow friction, requiring research sites to navigate multiple isolated software portals.

· Source Data Management and Interoperability: Integrating novel digital endpoints into existing clinical systems remains difficult in the absence of unified data standards.

· Role Ambiguity in Multi-Vendor Environments: The involvement of multiple independent technology and logistics vendors frequently blurs operational boundaries and oversight accountability.

· Operational Burden at Trial Sites: Research centers often encounter staffing constraints and incomplete standard operating procedures (SOPs) tailored to decentralized trial workflows.

· Regulatory and Cross-Border Privacy Complexity: Navigating divergent international data protection frameworks and evolving compliance expectations creates ongoing execution uncertainty.

· Participant Usability Barriers: Technical hurdles and digital literacy gaps can limit engagement and compliance among specific patient populations, particularly elderly participants.

These challenges show that simply using isolated digital tools cannot solve operational problems. Overcoming these hurdles requires an integrated partner who can connect digital tools, site operations, and regulatory compliance into a coordinated, patient-centric model.

Why Choose Tigermed for DCTs?

As DCT adoption continues to mature, the focus is increasingly shifting toward integrated, patient-centric trial design. Because decentralized trials have become an integration challenge, the value of an experienced Contract Research Organization (CRO) is no longer simply providing individual tools, but orchestrating the entire DCT ecosystem.

At Tigermed, we unite clinical operations, regulatory governance, and digital health tools into a cohesive model. By connecting site workflows with patient-friendly remote services, we help reduce investigators' administrative burden, enhance the participant experience, and maintain strict data integrity.

To further discuss customized DCT or CRO solutions, please visit the official Tigermed website or contact our team directly.

FAQs

1. What is the difference between traditional clinical trials and DCTs?

Traditional clinical trials require participants to visit designated research sites for all study visits, drug administration, and clinical assessments. In contrast, DCTs use digital tools, remote monitoring, and direct-to-patient logistics to distribute these activities across participants’ homes or local healthcare facilities.

2. Can DCTs improve participant recruitment and retention?

Yes. By reducing travel burdens to trial sites and offering remote pre-screening along with home visits, decentralized models make study participation much more convenient. This flexibility expands geographic reach, helping to improve participant compliance and retention rates throughout the trial lifecycle.

3. What are the potential applications of AI in DCTs?

AI is primarily applied to automate complex operational workflows, such as data management and anomaly detection, patient recruitment and cohort screening, and medical and safety monitoring. The industry views AI not only as an analytical tool but also as a proactive platform for orchestrating clinical trials.

Widespread AI integration remains exploratory and evolving.